Vesnarinone inhibits production of HIV-1 in cultured cells.
Vesnarinone, a synthetic oral cardiotonic agent that has been used for treatment of patients with congestive heart failure, was found to inhibit replication of HIV-1 in a peripheral blood lymphocytes model and in chronically infected macrophages at clinically achieved concentrations. Vesnarinone has no direct inhibitory activity against the reverse transcriptase of HIV-1, syncytium formation in short term assays, or retroviral protease. In addition, vesnarinone inhibits production of TNF-alpha and IL-6 by human peripheral blood mononucleated cells stimulated with LPS. These observations suggest that vesnarinone may be therapeutically useful in patients infected with HIV-1.
Maruyama
I
I
Department of Clinical Medicine, School of Medicine, Kagoshima University, Japan.
Maruyama
Y
Y
Nakajima
T
T
Kitajima
I
I
Osame
M
M
Zhao
J Q
JQ
Chen
I S
IS
Nakai
S
S
Ikeda
M
M
Yabu-uchi
Y
Y
D000998:Antiviral Agents / Q000494:pharmacology*; D002459:Cell Fusion / Q000187:drug effects; D002469:Cell Separation; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D016333:HIV Protease / Q000187:drug effects; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000382:microbiology*; D008264:Macrophages / Q000382:microbiology; D011719:Pyrazines; D011804:Quinolines / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000382:microbiology; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D016207:Cytokines; D011719:Pyrazines; D011804:Quinolines; C041667:vesnarinone; D016333:HIV Protease